Results
1 -
5 of
5Xu Tianfeng, Peng Ting, Ren Xiaomei, Zhang Lianwen, Yu Lei, Luo Jinfeng, Zhang Zhang, Tu Zhengchao, Tong Linjiang, Huang Zhaoru, Lu Xiaoyun, Geng Meiyu, Xie Hua, Ding Jian, Ding Ke.
C5-substituted pyrido[2,3-d]pyrimidin-7-ones as highly specific kinase inhibitors targeting the clinical resistance-related EGFRT790M mutant, Med. Chem. Commun., 2015 Chen Deheng, Guo Dexiang, Yan Ziqin, Zhao Yujun.
Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors, MedChemComm, 2018 AstraZeneca halts osimertinib-based cancer trials, Reactions Weekly Guan Longfei, Yang Hongbin, Cai Yingchun, Sun Lixia, Di Peiwen, Li Weihua, Liu Guixia, Tang Yun.
ADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness, MedChemComm, 2019 Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D..
Osimertinib, Pharmaceutical Substances [Online], Thieme: Stuttgart, (2016).